Quoin Pharmaceuticals, Ltd. (QNRX)
Nasdaq: QNRX · Pharmaceutical Preparations · filing with the SEC since 2016
Who owns Quoin Pharmaceuticals, Ltd.
As filed with the SECHolders of 5% or more
2
Stonepine Capital Management, LLC holds 9.99% of Ordinary Shares, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
8
report now, of 9 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Stonepine Capital Management, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Ordinary Shares · 10.6% in Feb 2, 2026
Integrated Core Strategies (US) LLC
SCHEDULE 13G · filed Jun 2, 2026 · Ordinary Shares, no par value per share · 4.6% in Feb 11, 2026
Resolute Capital Asset Partners LLC
SCHEDULE 13G · filed Dec 11, 2025 · American Depositary Shares, Each representing thirty-five(35) ordinary shares, no par value per share · reported falling below 5%
Armistice Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · American Depositary Shares, each representing one (1) Ordinary Shares, no par value per share QNRX The Nasdaq Stock Market LLC Ordinary S · reported falling below 5%, from 9.99% in Feb 14, 2025
ADAR1 Capital Management, LLC
SCHEDULE 13G/A · filed May 15, 2026 · American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share · reported falling below 5%, from 6.9% in Feb 17, 2026
Michael Myers
SCHEDULE 13D/A · filed Jan 28, 2025 · Ordinary Shares, no par value per share (represented by American Depositary Shares) · reported falling below 5%, from 6.9% in Jan 2, 2025
Denise Carter
SCHEDULE 13D/A · filed Jan 28, 2025 · Ordinary Shares, no par value per share (represented by American Depositary Shares) · reported falling below 5%, from 6.9% in Jan 2, 2025
Ikarian Capital, LLC
SCHEDULE 13G/A · filed Oct 7, 2026 · American Depositary Shares, each representing thirty-five (35) Ordinary Shares, no par value per share · reported falling below 5%, from 12.6% in Feb 6, 2026
Woodline Partners LP
SCHEDULE 13G/A · filed May 15, 2026 · Ordinary Shares, no par value per share · reported falling below 5%, from 9.5% in Feb 17, 2026
Aberdeen Group plc
SCHEDULE 13G/A · filed Apr 29, 2026 · American Depositary Shares, each representing Thirty-five (35) Ordinary Shares, no par value per share · reported falling below 5%, from 8.94% in Jan 28, 2026
What QNRX reports owning in othersstakes of 5% or more, and other ties
Quoin Pharmaceuticals, Ltd. reports no stake in another company in the record.
Insider tradesForm 4
0sales
4purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Oct 26, 2025 to Oct 26, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 26, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 10 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Myers Michael | Chief Executive Officer | 0 | $0 | 0 | 1 | $100,000 |
| Lawlor Sally Bridget | Chief Financial Officer | 0 | $0 | 0 | 1 | $0 |
| Carter Denise P. | Chief Operating Officer | 0 | $0 | 0 | 1 | $100,000 |
| Culverwell Anthony James | director | 0 | $0 | 0 | 1 | $0 |